1-3 of 3
Alessandro Rambaldi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy

Free
Josée Golay, Anna D’Amico, Gianmaria Borleri, Michela Bonzi, Rut Valgardsdottir, Rachele Alzani, Sabrina Cribioli, Clara Albanese, Enrico Pesenti, Maria Chiara Finazzi, Giulia Quaresmini, Dirk Nagorsen, Martino Introna, Alessandro Rambaldi
Journal: The Journal of Immunology
J Immunol (2014) 193 (9): 4739–4747.
https://doi.org/10.4049/jimmunol.1401550
Published: 01 November 2014
View articletitled, A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
Open the PDF for A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy in another window
Add to Citation Manager for A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
Includes: Supplementary data
Journal Articles

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

Free
Luca Bologna, Elisa Gotti, Fabio Da Roit, Tamara Intermesoli, Alessandro Rambaldi, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2013) 190 (1): 231–239.
https://doi.org/10.4049/jimmunol.1202645
Published: 01 January 2013
View articletitled, Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Open the PDF for Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy in another window
Add to Citation Manager for Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
Includes: Supplementary data
Journal Articles

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

Free
Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna, Josée Golay
Journal: The Journal of Immunology
J Immunol (2011) 186 (6): 3762–3769.
https://doi.org/10.4049/jimmunol.1000303
Published: 15 March 2011
View articletitled, Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Open the PDF for Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab in another window
Add to Citation Manager for Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
Includes: Supplementary data